132686-98-7

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl (6-methyl-5-oxo-5,6-dihydro-11H-pyrido[2,3-b][1,5]benzodiazepin-11-yl)acetate is used as a therapeutic agent for its potential anxiolytic, sedative, and muscle relaxant properties. Its chemical structure, including the tert-butyl and acetate groups, may contribute to its efficacy in managing anxiety disorders and other conditions that could benefit from the calming effects of benzodiazepines.
Used in Research and Development:
In the scientific community, tert-butyl (6-methyl-5-oxo-5,6-dihydro-11H-pyrido[2,3-b][1,5]benzodiazepin-11-yl)acetate serves as a valuable compound for research into the mechanisms of action of benzodiazepines. Its unique structural features allow for investigations into how modifications to the benzodiazepine framework can alter pharmacological activity, potentially leading to the development of new and improved medications for various mental health conditions.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 16287-28-8 6-methyl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one 
• 95-54-5 1,2-diamino-benzene 
• 2942-59-8 2-chloronicotinic acid 
• 10189-78-3 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

The treatment of HIV-1 infection using certain pyridodiazepines

Disclosed are novel pyridodiazepines. These compounds, as well certain known 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-ones are useful in the treatment of AIDS, ARC and related disorders associated with HIV infection.

Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones

Novel pyridobenzodiazepinones (I), pyridobenzodiazepinones (II), and dipyridodiazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM.In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.In general, lipophilic substituents are preferred on the A ring, whereassubstitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings.Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.Additional substituents on the A ring can be readily tolerated.The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridodiazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.